What is HC Wainwright's Forecast for TBPH FY2024 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Theravance Biopharma in a research report issued to clients and investors on Tuesday, February 25th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($1.01) for the year. HC Wainwright currently has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma's Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS and FY2027 earnings at ($0.43) EPS.

Theravance Biopharma Stock Up 0.9 %

Shares of NASDAQ:TBPH traded up $0.08 on Thursday, reaching $9.35. The company had a trading volume of 1,271,580 shares, compared to its average volume of 239,782. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.90. The stock has a 50-day moving average price of $9.33 and a 200 day moving average price of $8.93. The stock has a market capitalization of $459.78 million, a P/E ratio of -9.26 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $18.75 million for the quarter, compared to analysts' expectations of $29.90 million.

Remove Ads

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares of the company's stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Theravance Biopharma

A number of institutional investors have recently made changes to their positions in TBPH. Newtyn Management LLC increased its stake in shares of Theravance Biopharma by 5.7% in the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after purchasing an additional 258,337 shares during the period. BNP Paribas Financial Markets increased its stake in Theravance Biopharma by 88.9% during the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company's stock valued at $2,462,000 after acquiring an additional 143,781 shares during the period. Algert Global LLC bought a new position in Theravance Biopharma during the third quarter valued at about $851,000. Dimensional Fund Advisors LP increased its stake in Theravance Biopharma by 20.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares during the period. Finally, Millennium Management LLC increased its stake in Theravance Biopharma by 71.1% during the fourth quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company's stock valued at $1,815,000 after acquiring an additional 80,140 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.